1. Home
  2. MIST vs BOLD Comparison

MIST vs BOLD Comparison

Compare MIST & BOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MIST
  • BOLD
  • Stock Information
  • Founded
  • MIST 2003
  • BOLD 2018
  • Country
  • MIST Canada
  • BOLD United States
  • Employees
  • MIST N/A
  • BOLD N/A
  • Industry
  • MIST Biotechnology: Pharmaceutical Preparations
  • BOLD
  • Sector
  • MIST Health Care
  • BOLD
  • Exchange
  • MIST Nasdaq
  • BOLD Nasdaq
  • Market Cap
  • MIST 89.8M
  • BOLD 30.3M
  • IPO Year
  • MIST N/A
  • BOLD 2024
  • Fundamental
  • Price
  • MIST $2.17
  • BOLD $1.09
  • Analyst Decision
  • MIST Strong Buy
  • BOLD Buy
  • Analyst Count
  • MIST 2
  • BOLD 3
  • Target Price
  • MIST $7.50
  • BOLD $4.00
  • AVG Volume (30 Days)
  • MIST 638.1K
  • BOLD 367.5K
  • Earning Date
  • MIST 08-07-2025
  • BOLD 08-11-2025
  • Dividend Yield
  • MIST N/A
  • BOLD N/A
  • EPS Growth
  • MIST N/A
  • BOLD N/A
  • EPS
  • MIST N/A
  • BOLD N/A
  • Revenue
  • MIST N/A
  • BOLD N/A
  • Revenue This Year
  • MIST N/A
  • BOLD N/A
  • Revenue Next Year
  • MIST N/A
  • BOLD N/A
  • P/E Ratio
  • MIST N/A
  • BOLD N/A
  • Revenue Growth
  • MIST N/A
  • BOLD N/A
  • 52 Week Low
  • MIST $0.63
  • BOLD $1.00
  • 52 Week High
  • MIST $2.75
  • BOLD $4.72
  • Technical
  • Relative Strength Index (RSI)
  • MIST 74.51
  • BOLD N/A
  • Support Level
  • MIST $1.86
  • BOLD N/A
  • Resistance Level
  • MIST $1.97
  • BOLD N/A
  • Average True Range (ATR)
  • MIST 0.12
  • BOLD 0.00
  • MACD
  • MIST 0.02
  • BOLD 0.00
  • Stochastic Oscillator
  • MIST 93.22
  • BOLD 0.00

About MIST Milestone Pharmaceuticals Inc.

Milestone Pharmaceuticals Inc is a biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular medicines. Etripamil is a calcium channel blocker developed as a rapid-onset nasal spray to be administered by the patient to treat episodes of paroxysmal supraventricular tachycardia, or PSVT. The company has an ongoing Phase 2 clinical trial for patients with atrial fibrillation experiencing a rapid ventricular rate (AFib-RVR).

About BOLD Boundless Bio Inc. Common Stock

Boundless Bio Inc is a clinical-stage oncology company. The company is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells.

Share on Social Networks: